![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://i3.wp.com/mma.prnewswire.com/media/597589/4648918/Norgine_Logo.jpg?p=thumbnail&w=420&resize=420,280&ssl=1 "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma"){kind=logo}
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ --…
Combination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3
November 22, 2024 11:00 ET | Source: Orbus Therapeutics, Inc. – OS…
